ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financi...(illy in connection with theVancocin acqu...),Health

Date:10/30/2007

illy in connection with the Vancocin acquisition, net sales as of September 30, 2007 exceeded the maximum milestone threshold of $65.0 million. As a result, the Company recorded additional purchase price of $6.0 million to intangible assets in June 2007, which was paid to Lilly in the third quarter. No purchase price consideration will be due to Lilly relating to net sales occurring in the remainder of 2007.

Working Capital Highlights

As of September 30, 2007, ViroPharma's working capital was $573.3 million, which represents a $306.9 million increase from December 31, 2006, $31.2 million of which occurred in the third quarter of 2007. The nine month increase is primarily the result of the senior convertible notes issued on March 26, 2007 and cash flows.

Looking ahead in 2007

ViroPharma is updating previously announced guidance for the year 2007 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2007, ViroPharma anticipates the following:

-- Net product sales are expected to be between $202 to $208 million;

-- Gross margin rate for Vancocin is expected to be consistent with our

actual results in the first nine months of 2007;

-- Research and development (R&D) and marketing, general and

administrative (MG&A) expenses, excluding the impact of SFAS 123R, are

expected to be between $68 to $73 million.

-- The SFAS 123R impact to the above expenses will be approximately $8

million. Including the impact of SFAS 123R, the research and

development (R&D) and marketing, general and administrative (MG&A)

expenses are expected to be between $76 and $81 million.

Non-GAAP Disclosure
'/>"/>

SOURCE ViroPharma Incorporated Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Research reports that c-section deliveries are rising
6. Jharkhand reports 13,000 Malaria cases
7. Uganda Reports Failure To Contain Sleeping Sickness
8. WHO reports 36 million deaths world wide due to chronic diseases
9. Reports of Hantavirus infection in India raise concerns
10. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
11. China Reports Yet Another Bird Flu Case